Tim Smith

This research points to the notion that omalizumab may help individuals in more ways than a reduction of their sinonasal symptoms.

This research into EDS-FLU is significant, as there remain no medications approved by the FDA for chronic rhinosinusitis without nasal polyps.

These data were announced by Johnson & Johnson this week and show several encouraging findings regarding guselkumab’s use among patients of different skin types.

These data suggest the promise of morphine for cough among those with idiopathic pulmonary fibrosis, though longer term research may be necessary.

This study and its development of the Prurigo Control Test represents the first of its kind to assess chronic prurigo disease control.

This interview segment with Bhatia featured a discussion on addressing both unmet needs and lack of awareness among patients with actinic keratosis.

Bhatia discussed some of the major takeaways from his Winter Clinical presentation titled ‘What's New and Hot in AK Management.’

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.

These data indicate that e-cigarettes and nicotine patches were found not to negatively impact pregnant smokers in a significant way, though further study may be valuable.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

The updated labeling for dupilumab’s use resulted from the first phase 3 trial assessing a biologic within this subgroup of eczema patients.

In this interview, Del Rosso spoke on takeaways from his conference talk ‘What's New in the Medicine Chest? Acne, Rosacea, Actinic Keratoses, Psoriasis, Urticaria and Other Common Dermatoses.’

During this segment of his interview, Eingun James Song, MD, spoke about upcoming treatments for psoriasis and personalizing care for patients.

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

In this subgroup analysis data shown at Winter Clinical, findings indicated IGA success with topical roflumilast foam among seborrheic dermatitis patients.

In this discussion with E. James Song, MD, several unique clinical pearls for those in dermatology were described and had been drawn from Song’s Winter Clinical presentation.

The factors highlighted in this analysis may help dermatologists to better understand the concerns, misconceptions, and perceived risks reported by patients with HS.

These data, given sustainability targets in healthcare, may be considered by clinicians and by patients discussing DPIs.

The THESEUS study was conducted to look at current HS management and the influences on treatment decisions, with the goal of informing future randomized controlled trials.

These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.

These data indicate a significant ability of this treatment to address patients’ psoriatic symptoms in a comprehensive manner, despite varying characteristics and demographics.

In this analysis, the investigators note that the clinical association may be helpful to be taken into account as clinicians treat patients with HS.

These data indicate the necessity of further research to clarify any associations between COVID-19 infection, the virus’s associated vaccines, and progression of vitiligo.

This research had been conducted to look into prior studies linking daily pollen counts to respiratory allergic health outcomes.

These phase 2 data on hidradenitis suppurativa patients highlight new information on the use of lutikizumab as a treatment alternative.

These findings highlight the real access barriers faced by TGD individuals as well as the necessity of additional research to promote evidence-based hormonal acne treatments.

These findings may require further evaluation using classification of age range as well as severity of disease, allowing for more precise results.

The FDA decision on berdazimer gel, 10.3%, represents the second approved treatment for the viral-borne skin disease.

These data on PMF among coal miners suggest that urgent action may need to be taken to protect these workers from the preventable disease.

Despite these findings, the study highlights the need for a careful decision on the use of lung biopsy in older children given both benefits and risks.